umu.sePublications
Change search
ReferencesLink to record
Permanent link

Direct link
Efficacy and tolerability of reboxetine compared with citalopram: a double-blind study in patients with major depressive disorder
Umeå University, Faculty of Medicine, Department of Clinical Sciences, Psychiatry.
2006 (English)In: Journal of Clinical Psychopharmacology, ISSN 0271-0749, E-ISSN 1533-712X, Vol. 26, no 2, 121-127 p.Article in journal (Refereed) PublishedText
Abstract [en]

The objective of this study was to compare efficacy and tolerability of the selective noradrenalin reuptake inhibitor reboxetine with the selective serotonin reuptake inhibitor citalopram, in the treatment of major depressive disorder (MDD). In total, 357 outpatients with MDD were randomized to treatment with reboxetine 8-10 mg or citalopram 20-40 mg per day during 24 weeks. Primary end-point was change from baseline in the Hamilton Depression Rating Scale (HAM-D, 21 items). Sexual function/dysfunction was measured by the Sexual Function scale (SF). Observed case analysis showed that both treatments yielded a gradual reduction of HAM-D scores: reboxetine with -21.4 and citalopram with -22.1 points (NS). LOCF analysis showed a greater reduction of the HAM-D scores with citaloprarn compared with reboxetine (- 19.6 vs. - 17.8; P = 0.034). The response rate was 90.3% for reboxetine and 92.7% for citalopram (NS). The most common side effect in the reboxetine group was dry mouth, and in the citalopram group sexual dysfunction. At week 24, anorgasmia was reported by 5.9% of the sexually active women in the reboxetine group vs 39% in the citalopram group. The dropout number was 91 in the reboxetine group, and 54 in the citaloprarn group. To summarize, both treatments gave a satisfactory antidepressant effect. The side effect profile differed between the groups, with a notably high prevalence of sexual dysfunctions in the citalopram group. The high number of dropouts in the reboxetine group, is considered as a result of the non-titration starting dose of 8 mg reboxetine per day, which gave a high incidence of early side-effects.

Place, publisher, year, edition, pages
Philadelphia: Lippincott Williams & Wilkins, 2006. Vol. 26, no 2, 121-127 p.
Keyword [en]
serotonin reuptake inhibitors, tricyclic antidepressants, metaanalysis, discontinuation
National Category
Pharmacology and Toxicology Social and Clinical Pharmacy Psychiatry
Identifiers
URN: urn:nbn:se:umu:diva-119402DOI: 10.1097/01.jcp.0000204138.20417.c3ISI: 000236559600003PubMedID: 16633139OAI: oai:DiVA.org:umu-119402DiVA: diva2:927127
Available from: 2016-05-11 Created: 2016-04-18 Last updated: 2016-05-11Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Bodlund, Owe
By organisation
Psychiatry
In the same journal
Journal of Clinical Psychopharmacology
Pharmacology and ToxicologySocial and Clinical PharmacyPsychiatry

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 7 hits
ReferencesLink to record
Permanent link

Direct link